Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer
- Authors
- Yu, W., Chai, H., Li, Y., Zhao, H., Xie, X., Zheng, H., Wang, C., Wang, X., Yang, G., Cai, X., Falck, J.R., and Yang, J.
- ID
- ZDB-PUB-120802-11
- Date
- 2012
- Source
- Toxicology and applied pharmacology 264(1): 73-83 (Journal)
- Registered Authors
- Li, Ying
- Keywords
- cytochrome P450, angiogenesis, VEGF-A, TIMP-2, breast cancer
- MeSH Terms
-
- Amidines/pharmacology
- Animals
- Breast Neoplasms/blood supply
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology*
- Cell Line, Tumor
- Cell Proliferation
- Chick Embryo
- Chorioallantoic Membrane
- Cytochrome P-450 Enzyme System/genetics*
- Female
- Gene Expression Regulation, Neoplastic*
- Human Umbilical Vein Endothelial Cells
- Humans
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Mitogen-Activated Protein Kinase 1/metabolism
- Mitogen-Activated Protein Kinase 3/metabolism
- Neovascularization, Pathologic/physiopathology*
- Phosphatidylinositol 3-Kinases/metabolism
- Proto-Oncogene Proteins c-akt/metabolism
- RNA, Messenger/metabolism
- Tissue Inhibitor of Metalloproteinase-2/metabolism
- Vascular Endothelial Growth Factor A/metabolism
- Xenograft Model Antitumor Assays
- Zebrafish
- PubMed
- 22841774 Full text @ Tox. App. Pharmacol.
Cytochrome P450 (CYP) 4Z1, a novel CYP4 family member, is over-expressed in human mammary carcinoma and associated with high-grade tumors and poor prognosis. However, the precise role of CYP4Z1 in tumor progression is unknown. Here, we demonstrate that CYP4Z1 overexpression promotes tumor angiogenesis and growth in breast cancer. Stable expression of CYP4Z1 in T47D and BT-474 human breast cancer cells significantly increased mRNA expression and production of vascular endothelial growth factor (VEGF)-A, and decreased mRNA levels and secretion of tissue inhibitor of metalloproteinase-2 (TIMP-2), without affecting cell proliferation and anchorage-independent cell growth in vitro. Notably, the conditioned medium from CYP4Z1-expressing cells enhanced proliferation, migration and tube formation of human umbilical vein endothelial cells, and promoted angiogenesis in the zebrafish embryo and chorioallantoic membrane of the chick embryo. In addition, there were lower levels of myristic acid and lauric acid, and higher contents of 20-hydroxyeicosatetraenoic acid (20-HETE) in CYP4Z1-expressing T47D cells compared with vector control. CYP4Z1 overexpression significantly increased tumor weight and microvessel density by 2.6-fold and 1.9-fold in human tumor xenograft models, respectively. Moreover, CYP4Z1 transfection increased the phosphorylation of ERK1/2 and PI3K/Akt, while PI3K or ERK inhibitors and siRNA silencing reversed CYP4Z1-mediated changes in VEGF-A and TIMP-2 expression. Conversely, HET0016, an inhibitor of the CYP4 family, potently inhibited the tumor-induced angiogenesis with associated changes in the intracellular levels of myristic acid, lauric acid and 20-HETE. Collectively, these data suggest that increased CYP4Z1 expression promotes tumor angiogenesis and growth in breast cancer partly via PI3K/Akt and ERK1/2 activation.